Physician profile
Lynette Posorske
NPI 1598728305
$47,250.80
in general payments reported to CMS, 2019-2025
18 companies · $352 in 2025
The $352 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $2,852 · 2021: $8,764 · 2022: $4,341 · 2023: $1,704 · 2024: $1,669 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,725.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $26,235.67 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $13,875.20 | 2019-2025 | Dificid, Zerbaxa, Recarbrio |
| Viiv Healthcare Company | $3,487.16 | 2019-2025 | Cabenuva, Dovato, Rukobia |
| Abbvie INC. | $892.09 | 2019-2025 | |
| Janssen Biotech, INC. | $624.13 | 2019-2023 | Symtuza |
| Theratechnologies INC. | $597.78 | 2019-2025 | Egrifta, Trogarzo |
| Insmed, INC. | $558.65 | 2019-2024 | Arikayce |
| Napo Pharmaceuticals INC | $208.65 | 2019-2022 | |
| Janssen Products, LP | $175.07 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $163.69 | 2022-2024 | Xerava |
| Paratek Pharmaceuticals, INC. | $155.29 | 2019-2023 | Nuzyra |
| Shionogi INC | $87.64 | 2022-2024 | Fetroja |
| Allergan, INC. | $69.32 | 2019-2020 | |
| Melinta Therapeutics, LLC | $31.65 | 2022 | |
| Novartis Pharmaceuticals Corporation | $27.40 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $23.88 | 2022 | |
| Mylan Institutional INC. | $20.59 | 2019 | |
| Fortovia Therapeutics, INC. | $16.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynette Posorske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.